The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.

The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc., a non-profit military medical research organization headquartered in Bethesda, Maryland, operates as a prime contractor and recipient for the federal government, delivering military medical research, clinical studies, infectious disease countermeasures, vaccine development, and casualty care innovation to the Department of Defense, the Department of Veterans Affairs, the National Institutes of Health, and related federal agencies. The foundation competes under full-and-open procurement and receives funding without SBA set-aside designations. It holds substantial indefinite delivery vehicles including single-award IDCs with the Uniformed Services University of the Health Sciences and the Veterans Integrated Service Network, alongside GSA Schedule positions offering 89 labor categories spanning clinical research coordinators, engineers, psychologists, and senior leadership roles at rates from $43.98/hr to $263.48/hr.

The foundation's customer concentration is heavily skewed toward DOD. The Defense Health Agency dominates by dollars ($10.48 billion combined potential value across 240 awards, approximately 79% of the top five customer value share), while the Uniformed Services University of the Health Sciences leads by award count (1,393 awards, $259.3 million) but carries substantially lower average award magnitude. Together, these two customers account for 74% of recent awards. The National Institute of Allergy and Infectious Diseases (115 awards, $961.5 million) and the Army Medical Command (132 awards, $300.9 million) round out the primary federal customer base. This concentration reflects the foundation's mission-driven positioning as a military medical research partner; DHA and USUHS account for approximately 95% of the top five customers' combined potential value.

Recent capability work spans infectious disease surveillance and countermeasures, traumatic brain injury diagnostics and treatment, post-traumatic stress disorder interventions, casualty care innovation, radiation medical countermeasures, vaccine development, and deployment health research. Representative prime contracts include a $11.1 million delivery order under the Omnibus IV Military Medical Research and Development vehicle for development of clinical practice guidelines supporting infectious disease care (awarded September 2024 by Uniformed Services University, $4.6 million invoiced in FY2025 across 21 FTEs); a $3.58 million purchase order from the Defense Health Agency for continued research and development on casualty care assessment from the Russo-Ukraine War (awarded September 2025); a $1.21 million contract from Uniformed Services University for the Meningococcal Immunization Against Gonococcal Infection (MAGI) trial with Search Research Foundation as subcontractor (awarded September 2025); and a $5.99 million grant for research to provide human health and performance countermeasures, knowledge, technologies, and tools to enable safe space exploration under the Human Research Program (awarded February 2025 by NASA's Shared Services Center). The foundation also holds a $991,851 Other Transaction Agreement with the Joint Program Executive Office for Chemical and Biological Defense for procurement of expanded access protocols for CBRN enabling technologies (awarded June 2026, running through January 2031).

The foundation's federal grant footprint is extensive and concentrated in DOD and HHS programs. Federal grant funding flows primarily through the Uniformed Services University Medical Research Projects program (CFDA 12.750), the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420), and the National Institute of Allergy and Infectious Diseases Allergy and Infectious Diseases Research program (CFDA 93.855). Recent grant awards as prime recipient include $25.864 million for brain injury and disease prevention, treatment, and research (USUHS, September 2025, running through September 2028); $13.268 million for development of 3D human microtissue models for cancer and infectious disease preparedness (USUHS, September 2026, running through August 2028); $9.043 million for prolonged field care research in austere environments (USUHS, August 2026, running through July 2029); $7.5 million for integrated health research addressing mental, emotional, developmental, and behavioral conditions in children (USUHS, September 2025, running through September 2028); $6.430 million for the Defense & Veterans Center for Integrative Pain Management (USUHS, February 2026, running through March 2031); $5.292 million for the Consortium for Defense Psychology Training and Operations (USUHS, September 2026, running through September 2028); $4.9 million for a randomized clinical trial of MDMA-assisted therapy for military service members with PTSD (Defense Health Agency, September 2025, running through August 2028); and $4.29 million for development of machine learning models utilizing multimodal assessments from smart wearables for enhanced PTSD screening and precision diagnosis (USUHS, September 2025, running through September 2029). The foundation also received $5 million from the National Endowment for the Arts to support creative arts therapies and non-clinical arts engagement across Creative Forces clinical sites (awarded July 2025, running through June 2027).

The foundation serves as a prime recipient in approximately 91% of its federal awards and subcontracts in approximately 9%. Across SCI-reportable prime contracts, the foundation self-performs substantially all work, with sub-contractor share averaging 0% of total contractor hours. The foundation does, however, pass through research funding to leading academic institutions and specialized research organizations as sub-recipients and sub-awardees. Recent sub-awardees include Tufts College, Johns Hopkins University, University of Pennsylvania, UCSF, Georgetown University, University of Idaho, University of Minnesota, Arizona State University, Emory University, Duke University, Kennedy Krieger Institute, The Children's Hospital of Philadelphia Research Institute, The Geneva Foundation, RTI International, Albert Einstein College of Medicine, and Palo Alto Veterans Institute for Research. Sub-contract and grant sub-award work ranges from vaccine platform development and clinical trial support to machine learning model development, biomarker analysis, and specialized research infrastructure provision.

Service Contract Inventory data show SCI-reportable invoiced revenue of $12.1 million across FY2022–FY2025, with reported FTE delivery at 5.2 FTEs (FY2022), 11.5 FTEs (FY2023), 12.2 FTEs (FY2024), and 32.1 FTEs (FY2025). On federal services contracts captured in SCI, median government-paid rates ran around $92.03/hr, with the 90th percentile at $124.48/hr and the 10th percentile at $75.92/hr. SCI data represent a strict subset of the foundation's federal services activity and a smaller fraction of total enterprise revenue; the source does not carry non-SCI service contracts, goods, products, micro-purchases, or non-federal revenue. Activity per year (last five fiscal years) shows 124 awards (2022), 197 (2023), 218 (2024), 161 (2025), and 105 awards year-to-date through mid-2026. Combined potential value across all 2,685 prime and sub awards is $13.2 billion, with $11.04 billion obligated (84% realization). Within the next twenty-four months, 353 awards carrying combined potential value of $284.8 million face recompete cliff; this recompete opportunity anchors the foundation's pipeline risk and competitive renewal exposure.

The foundation administers research operations through three named subsidiaries: HJF Medical Research International Inc., Camris International, LLC, and HJF Medical Research International, LTD / GTE, leveraging subsidiary entities to structure research program delivery and administrative functions across diverse funding vehicles and customer requirements.